Topic Review
Ultrasonic Microbubble Cavitation in Tumor Therapy
Chemotherapy has an essential role not only in advanced solid tumor therapy intervention but also in society’s health at large. Chemoresistance, however, seriously restricts the efficiency and sensitivity of chemotherapeutic agents, representing a significant threat to patients’ quality of life and life expectancy. How to reverse chemoresistance, improve efficacy sensitization response, and reduce adverse side effects need to be tackled urgently. Consequently, studies on the effect of ultrasonic microbubble cavitation on enhanced permeability and retention (EPR) have attracted the attention of researchers. Compared with the traditional targeted drug delivery regimen, the microbubble cavitation effect, which can be used to enhance the EPR effect, has the advantages of less trauma, low cost, and good sensitization effect, and has significant application prospects.
  • 862
  • 15 Aug 2022
Topic Review
Riboswitches
Riboswitches reside in the 5'- untranslated region of RNA and regulate genes involved in the homeostasis of molecules or Ions they bind to. Since their discovery at the beginning of this century, some of the riboswitches have been regarded as potential antibacterial targets due to their role in the regulation of the homeostasis of the essential metabolites. The pharmacological potential of such riboswitches is being explored u various approaches which include fragment screening, high-throughput screening and rational ligand design guided by X-ray crystallography.
  • 860
  • 24 Feb 2021
Topic Review
Extracellular Vesicles
Tobacco smoking is prevalent among people living with HIV (PLWH). It is known to increase viral replication and exacerbate HIV associated conditions. Some reports demonstrate a conflicting impact of cigarette smoke on PLWHA in terms of neurocognitive disorders, which further strengthens the necessity to study whether cigarette smoking is a causative factor for HAND in PLWHA. One possible mechanistic pathway of tobacco smoking-induced HIV pathogenesis and HAND could be the transportation of oxidative stress-related agents and inflammatory modulators via extracellular vesicles (EVs). EV are nanosized vesicles, that are formed and released from most of the mammalian cells and these are considered as cellular messengers because of their capability to transport the functional messages from cells to other distant cells. This review focuses on recent advances in the field of EVs with an emphasis on smoking-mediated HIV pathogenesis and HIV-associated neuropathogenesis.
  • 858
  • 06 Jan 2021
Topic Review
Magnetic nanoparticles: coating and applications
Magnetic nanoparticles (MNPs) have great potential in material science, drug delivery, magnetic resonance imaging, and therapeutic applications. Indeed, a number of iron oxide nanoparticles have been withdrawn due to their poor clinical performance and/or toxicity issues. MNPs have successfully been converted into water-soluble, stable, bio-accessible systems using the proprietary various coating strategy. Herein, we summarize the data of applications and coating strategies of MNPs.
  • 856
  • 11 Jan 2022
Topic Review
Ad-Dressing Stem Cells
Stem cell encapsulation is a technique that utilizes various biomaterials for the creation of a semi-permeable membrane that encases the stem cells. Stem cell encapsulation can be accomplished by employing a great variety of natural and/or synthetic hydrogels, and offers many benefits in regenerative medicine, including protection from host’s immune system and mechanical stress, improved cell viability, proliferation and differentiation, cryopreservation and controlled and continuous delivery of the stem cell secreted therapeutic agents. In this review, we report and discuss almost all natural and synthetic hydrogels used in stem cell encapsulation, along with the benefits that these materials, alone or in combinations, could offer to cell therapy through a functional cell encapsulation.
  • 856
  • 08 Jan 2021
Topic Review
Flecainide in Ventricular Arrhythmias
Flecainide is an IC antiarrhythmic drug (AAD) that received in 1984 Food and Drug Administration approval for the treatment of sustained ventricular tachycardia (VT) and subsequently for rhythm control of atrial fibrillation (AF). Currently, flecainide is mainly employed for sinus rhythm maintenance in AF and the treatment of idiopathic ventricular arrhythmias (IVA) in absence of ischaemic and structural heart disease on the basis of CAST data. Recent studies enrolling patients with different structural heart diseases demonstrated good effectiveness and safety profile of flecainide.
  • 855
  • 10 Sep 2021
Topic Review
Mechanisms of Resistance to Gemcitabine
Gemcitabine is still the standard-of-care chemotherapeutic drug for pancreatic ductal adenocarcinoma (PDAC). However, the response rate is quite low. There are multiple mechanisms and participants in gemcitabine resistance.
  • 852
  • 01 Jun 2022
Topic Review
Polyphenols and Stroke
Polyphenols are an important family of molecules of vegetal origin present in many medicinal and edible plants, which represent important alimentary sources in the human diet. Polyphenols are known for their beneficial health effects and have been investigated for their potential protective role against various pathologies, including cancer, brain dysfunctions, cardiovascular diseases and stroke.
  • 851
  • 15 Jan 2021
Topic Review
Clinical Trials of Parkinson’s Disease
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that currently has no cure, but treatments are available to improve PD symptoms and maintain quality of life.
  • 851
  • 03 Aug 2021
Topic Review
β-Lactamase Inhibitors
The inhibitors of β-lactamases (BLI) have gained a prominent role in the safeguard of beta-lactams. In the last years, new β-lactam–BLI combinations have been registered or are still under clinical evaluation, demonstrating their effectiveness to treat complicated infections. It is also noteworthy that the pharmacokinetics of BLIs partly matches that of β-lactams companions, meaning that some clinical situations, as well as renal impairment and renal replacement therapies, may alter the disposition of both drugs. Common pharmacokinetic characteristics, linear pharmacokinetics across a wide range of doses, and known pharmacokinetic/pharmacodynamic parameters may guide modifications of dosing regimens for both β-lactams and BLIs. However, comorbidities (i.e., burns, diabetes, cancer) and severe changes in individual pathological conditions (i.e., acute renal impairment, sepsis) could make dose adaptation difficult, because the impact of those factors on BLI pharmacokinetics is partly known. Therapeutic drug monitoring protocols may overcome those issues and offer strategies to personalize drug doses in the intensive care setting. Further prospective clinical trials are warranted to improve the use of BLIs and their β-lactam companions in severe and complicated infections. 
  • 850
  • 11 Jul 2021
  • Page
  • of
  • 106
Video Production Service